Perspectives on quality intelligence from the team building Qualera. Regulatory analysis, audit methodology, and practical guidance for MedTech quality leaders navigating QMSR, ISO 13485, and the new era of FDA inspection.
The FDA's Quality Management System Regulation took effect February 2, 2026. We break down the new inspection paradigm under Compliance Program 7382.850 — what inspectors will ask for, what's changed from the old 820 playbook, and where most quality systems have gaps they don't know about yet.
For a quarter century, quality teams operated under QSIT's predictable inspection regime. That script has been shredded. CP 7382.850 eliminates the checklist mentality altogether — here's what replaces it.
Audit MethodologyUnder QMSR, supplier audit reports are now subject to FDA inspection. This single change transforms every supplier audit from an internal document into potential inspection evidence.
Quality LeadershipThe unspoken compact — be candid because the FDA will never see this document — has been voided. Internal audit reports, supplier audits, and management review records are now subject to investigator review.
Audit MethodologyTraditional audits sample 5–15% of your QMS documents. Qualera reads every SOP, work instruction, and form. Here's why that distinction matters — and what auditors find when nothing is left unread.
Quality LeadershipUnder QMSR, management review outputs are FDA-inspectable records. Most companies are still producing management reviews that look like 2019. That's no longer a process gap — it's a compliance exposure.
QMSR & Regulatory IntelligenceThe FDA's new compliance program guide reshapes how inspections are planned and executed. We analyze the key sections, cross-reference with ISO 13485:2016, and identify the process areas most likely to receive early scrutiny.
Audit MethodologyQMSR removed the old 820 exemption that shielded internal audit reports from FDA review. Your audit program, findings, and evidence are now fair game during inspection. Here's how to prepare.
Quality LeadershipPE firms and strategic acquirers are getting smarter about quality risk. If your quality system can't withstand a structured diligence review, it will cost you at the deal table. What quality leaders can do now.
No articles in this category yet. Check back soon.